Company / Operating Cash Flow per Share
Dyne Therapeutics, Inc. Operating Cash Flow per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.86
FY2024
5-year range
-$3.23 / -$2.35
FY2020-FY2024
Trend
+6.7%
vs FY2023
Sector context
#163 of 210
Health Care
What the data says
Dyne Therapeutics, Inc.'s operating cash flow per share of $-2.86 is lower than 78% of companies in the Health Care sector (FY2024). Operating Cash Flow per Share returned to growth in FY2024 after 2 years of decline, reaching $-2.86.
Based on SEC 10-K filings.
-2.86 in FY2024.
Declined from $-2.76 to $-2.86 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 210This company -$2.86 Sector average $5.30
▼
-153.9% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 6.7% year-over-year.
- Ranks #163 out of 210 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.86 | +6.7% |
| FY2023 | -$3.06 | -10.8% |
| FY2022 | -$2.76 | -17.6% |
| FY2021 | -$2.35 | +27.3% |
| FY2020 | -$3.23 | +33.3% |
| FY2019 | -$4.84 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026